Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025.

The Seattle-based firm will focus on its SC291 and UP421 programs for B-cell mediated autoimmune diseases and type 1 diabetes, respectively, with multiple data readouts expected in the next two years.

The company is now concentrating its resources on advancing SC291, its anti-CD19 allogeneic CAR-T therapy, for the treatment of B-cell mediated autoimmune diseases (AID). This new focus has led to the ...

[Click here for information about joining the class action] On November 4, 2024, Sana issued a press release announcing that it "will suspend development of both SC291 in oncology and of SC379 ...

Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships ...

Under plans to extend the company’s cash runway into 2026, Sana said it has halted development of its CD19-directed allogeneic CAR T-cell therapy, dubbed SC291, in cancer and will instead focus ...